Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02947386 · ClinicalTrials.gov registry record · Phase 1
Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT02947386 is a Phase 1 study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 7 participants.
The verdict
NCT02947386, a Phase 1 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This phase I/II trial studies the best dose and side effects of nimotuzumab when giving together with nivolumab and to see how well they work in treating patients with non-small cell lung cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Monoclonal antibodies, such as nimotuzumab and nivolumab, may block tumor growth in different ways by targeting certain cells.
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Nivolumab
- BIOLOGICAL Nimotuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2017-06-29 |
| Est. Completion | 2022-09-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02947386
The ClinicalTrials.gov registry entry for NCT02947386 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02947386 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02947386 about?
NCT02947386 is a clinical study titled "Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer". This phase I/II trial studies the best dose and side effects of nimotuzumab when giving together with nivolumab and to see how well they work in treating patients with non-small cell lung cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Mon...
What is the current status of trial NCT02947386?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2017-06-29. Estimated completion is 2022-09-08.
What interventions are being tested in trial NCT02947386?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Nivolumab (BIOLOGICAL), Nimotuzumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02947386?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.